Abstract

BackgroundBone is the most common metastatic site of Breast invasive carcinoma (BRCA). In this study, the bone metastasis-specific regulation network of BRCA was constructed based on prognostic stemness-related signatures (PSRSs), their upstream transcription factors (TFs) and downstream pathways.MethodsClinical information and RNA-seq data of 1,080 primary BRCA samples (1,048 samples without bone metastasis and 32 samples with bone metastasis) were downloaded from The Cancer Genome Atlas (TCGA). The edgeR method was performed to identify differential expressed genes (DEGs). Next, mRNA stemness index (mRNAsi) was calculated by one-class logistic regression (OCLR). To analyze DEGs by classification, similar genes were integrated into the same module by weighted gene co-expression network analysis (WGCNA). Then, univariate and multivariate Cox proportional hazard regression were applied to find the PSRSs. Furthermore, PSRSs, 318 TFs obtained from Cistrome database and 50 hallmark pathways quantified by GSVA were integrated into co-expression analysis. Significant co-expression patterns were used to construct the bone metastasis-specific regulation network. Finally, spatial single-cell RNA-seq and chromatin immunoprecipitation sequence (ChIP-seq) data and multi-omics databases were applied to validate the key scientific hypothesis in the regulation network. Additionally, Connectivity Map (CMap) was utilized to select the potential inhibitors of bone metastasis-specific regulation network in BRCA.ResultsBased on edgeR and WGCNA method, 43 PSRSs were identified. In the bone metastasis-specific regulation network, MAF positively regulated CD248 (R = 0.435, P < 0.001), and hallmark apical junction was the potential pathway of CD248 (R = 0.353, P < 0.001). This regulatory pattern was supported by spatial single-cell RNA sequence, ChIP-seq data and multi-omics online databases. Additionally, alexidine was identified as the possible inhibitor for bone metastasis of BRCA by CMap analysis.ConclusionPSRSs played important roles in bone metastasis of BRCA, and the prognostic model based on PSRSs showed good performance. Especially, we proposed that CD248 was the most significant PSRS, which was positively regulated by MAF, influenced bone metastasis via apical junction pathway. And this axis might be inhibited by alexidine, which providing a potential treatment strategy for bone metastasis of BRCA.

Highlights

  • Breast Invasive Carcinoma (BRCA) was the most common tumor in female, which originated from ducts and acinar epithelium at all levels of the breast, and most patients suffered from malignant epithelial tumor

  • BRCA was a common tumor in female, and patients with bone metastasis suffered from the pain and the risk of fracture and even death [4]

  • None of the study reported the correlation of MAF and CD248, we proposed that MAF positively regulated the transcription of CD248: promoted the function of the transcript in cell adhesion, invasion and migration, and regulated osteoblast function [36, 40, 41]

Read more

Summary

Introduction

Breast Invasive Carcinoma (BRCA) was the most common tumor in female, which originated from ducts and acinar epithelium at all levels of the breast, and most patients suffered from malignant epithelial tumor. Estimated by American Cancer Society (ACS), there were 279,100 new cases, and 42,690 new death BRCA patients in 2020 [2]. The five-year survival rate for BRCA in stage I, II, III, and IV were 98, 92, 75, and 27% according to the statistic from 2009 to 2015, respectively [3]. The five-year survival rate of primary BRCA was high, the five-year survival rate of bone metastasis was only 20%, and patients were trapped in a vicious cycle between osteolytic degeneration and proliferation of cancer cells [4]. Bone is the most common metastatic site of Breast invasive carcinoma (BRCA). The bone metastasis-specific regulation network of BRCA was constructed based on prognostic stemness-related signatures (PSRSs), their upstream transcription factors (TFs) and downstream pathways

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.